Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | Director | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 50,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
F2: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 6,021 · Balance 11,252 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 4,444 · Balance 6,808 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $39.76 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 17,500 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 11,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:38 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001761768-26-000003 · ownership.xml · derivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 20:04 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000950170-25-113243 · ownership.xml · derivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-09-03 F1 · derivative.exercise_date: Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 11,000 | Not disclosed Strike: $64.14 | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · derivative · entry 6 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7 · price: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,520 | Not disclosed Strike: $45.66 | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · derivative · entry 5 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,500 | Not disclosed Strike: $39.76 | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · derivative · entry 4 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2028-12-05 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · nonDerivative · entry 3 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · nonDerivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003539 · form4.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,252 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 23:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,808 | $58.75 | $399,970.00 |
DisclosureSEC source: 0001628280-24-000319 · wk-form4_1704324760.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,273 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001039 · marketforms-58263.xml · derivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001039 · marketforms-58263.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,465 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000845 · marketforms-55083.xml · derivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000845 · marketforms-55083.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · derivative · entry 12 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: CommonStock · 7,500 shares Expires 2028-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F11 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 200 | $207.83 | $41,565.00 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 11 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $207.74 to $207.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,100 | $206.63 | $227,296.52 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 10 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,675 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $206.215 to $206.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 975 | $205.26 | $200,124.80 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 9 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $205.00 to $205.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,205 | $204.43 | $246,333.21 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 8 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $204.00 to $204.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,579 | $203.43 | $321,218.97 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 7 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,955 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $202.97 to $203.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 960 | $201.99 | $193,910.78 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 6 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,534 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $201.63 to $202.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 462 | $200.90 | $92,817.60 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 5 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $200.55 to $201.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 719 | $200.05 | $143,839.40 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 4 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,956 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $199.51 to $200.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 250 | $198.48 | $49,621.00 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 3 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,675 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $198.23 to $199.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 50 | $197.14 | $9,857.00 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,925 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 02:47 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 7,500 | $39.76 | $298,200.00 |
DisclosureSEC source: 0001214659-21-001095 · marketforms-51311.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 2,155 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000680 · marketforms-50977.xml · derivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000680 · marketforms-50977.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 01:29 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $113.20 | $0.00 |
DisclosureSEC source: 0001214659-20-000197 · marketforms-47238.xml · derivative · entry 2 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-01-02 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 01:29 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000197 · marketforms-47238.xml · nonDerivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 17, 2019 Filed Jan 23, 2019 00:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $64.14 | $0.00 |
DisclosureSEC source: 0001214659-19-000459 · marketforms-43766.xml · derivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| December 06, 2018 Filed Dec 13, 2018 23:57 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001214659-18-007681 · marketforms-43510.xml · derivative · entry 1 Martinez Maria E · CIK 0001761768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-12-05 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.